See more : Aerie Pharmaceuticals, Inc. (AERI) Income Statement Analysis – Financial Results
Complete financial analysis of Movano Inc. (MOVE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Movano Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- ClimateRock (CLRCU) Income Statement Analysis – Financial Results
- BASF India Limited (BASF.BO) Income Statement Analysis – Financial Results
- Biophytis S.A. (BPTS) Income Statement Analysis – Financial Results
- American Campus Communities, Inc. (ACC) Income Statement Analysis – Financial Results
- Sutlej Textiles and Industries Limited (SUTLEJTEX.BO) Income Statement Analysis – Financial Results
Movano Inc. (MOVE)
About Movano Inc.
Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medtech and consumer devices. Its platform uses radiofrequency technology, which enables the creation of sensors that are small enough to fit into wearable devices and other small form factors. The company develops Movano Ring that measures heart rate, heart rate variability, sleep, respiration, temperature, blood oxygen saturation, steps, and calories, as well as incorporates women-centric features and design. It is also developing non-invasive continuous glucose monitoring and cuffless blood pressure monitoring features to its technology platform. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 158.00K | 134.00K | 74.00K | 13.00K | 11.00K | 3.00K |
| Gross Profit | -158.00K | -134.00K | -74.00K | -13.00K | -11.00K | -3.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.89M | 18.99M | 13.43M | 8.37M | 6.52M | 2.89M |
| General & Administrative | 0.00 | 1.93K | 6.38M | 2.73M | 2.00M | 662.18K |
| Selling & Marketing | 0.00 | 11.47M | 0.00 | 0.00 | 0.00 | -58.18K |
| SG&A | 12.80M | 11.47M | 6.38M | 2.73M | 2.00M | 604.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 72.00K | 0.00 |
| Operating Expenses | 29.69M | 30.46M | 19.80M | 11.11M | 8.51M | 3.49M |
| Cost & Expenses | 29.69M | 30.46M | 19.80M | 11.11M | 8.51M | 3.50M |
| Interest Income | 0.00 | 133.00K | 22.00K | 27.00K | 59.00 | 0.00 |
| Interest Expense | 0.00 | 133.00K | 883.00K | 1.00M | 0.00 | 0.00 |
| Depreciation & Amortization | 158.00K | 134.00K | 74.00K | 13.00K | 11.00K | 3.00K |
| EBITDA | -29.13M | -30.20M | -20.82M | -11.07M | -8.50M | -3.49M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.69M | -30.46M | -19.80M | -11.11M | -8.51M | -3.50M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 407.00K | 133.00K | -1.97M | -1.92M | 72.00K | 8.00K |
| Income Before Tax | -29.28M | -30.33M | -21.77M | -13.03M | -8.44M | -3.49M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -133.00K | 809.00K | 1.00M | -160.86K | 0.00 |
| Net Income | -29.28M | -30.20M | -22.58M | -14.04M | -8.44M | -3.49M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.51 | -13.71 | -10.34 | -6.55 | -3.94 | -1.63 |
| EPS Diluted | -9.51 | -13.71 | -10.34 | -6.55 | -3.94 | -1.63 |
| Weighted Avg Shares Out | 3.08M | 2.20M | 2.18M | 2.14M | 2.14M | 2.14M |
| Weighted Avg Shares Out (Dil) | 3.08M | 2.20M | 2.18M | 2.14M | 2.14M | 2.14M |
MIT Selects Movano Health for Groundbreaking Study on Long COVID and Chronic Lyme Disease
TREASURIES-US yields drift higher in quiet trading session
Movano Inc. (MOVE) Q1 2024 Earnings Call Transcript
Movano Health Reports Q1 2024 Financial Results and Provides Business Update
Movano Health Submits Exemplary Sp02 Clinical Trial Results in Key Step Towards FDA 510(k) Clearance Decision
Movano Health to Report First Quarter 2024 Financial Results on Wednesday May 15, 2024
Movano Health Closes $24 Million Private Placement
Movano Health Reports 2023 Financial Results and Provides Business Update
Movano Health Announces $24 Million Private Placement
Movano Health Secures Strategic Investment from Tier-One Multi-Billion Dollar Medical Device Company
Source: https://incomestatements.info
Category: Stock Reports